Recombinant Human Melanoma-Associated Antigen C2 (MAGEC2) Protein (His&Myc)

Name: Recombinant Human Melanoma-Associated Antigen C2 (MAGEC2) Protein (His&Myc)
Brand: Beta LifeScience
SKU: BLC-06714P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Melanoma-Associated Antigen C2 (MAGEC2) Protein (His&Myc) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	Q9UBF1
Target Symbol	MAGEC2
Synonyms	(Cancer/testis antigen 10)(CT10)(Hepatocellular carcinoma-associated antigen 587)(MAGE-C2 antigen)(MAGE-E1 antigen)
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	N-10His&C-Myc
Target Protein Sequence	MPPVPGVPFRNVDNDSPTSVELEDWVDAQHPTDEEEEEASSASSTLYLVFSPSSFSTSSSLILGGPEEEEVPSGVIPNLTESIPSSPPQGPPQGPSQSPLSSCCSSFSWSSFSEESSSQKGEDTGTCQGLPDSESSFTYTLDEKVAELVEFLLLKYEAEEPVTEAEMLMIVIKYKDYFPVILKRAREFMELLFGLALIEVGPDHFCVFANTVGLTDEGSDDEGMPENSLLIIILSVIFIKGNCASEEVIWEVLNAVGVYAGREHFVYGEPRELLTKVWVQGHYLEYREVPHSSPPYYEFLWGPRAHSESIKKKVLEFLAKLNNTVPSSFPSWYKDALKDVEERVQATIDTADDATVMASESLSVMSSNVSFSE
Expression Range	1-373aa
Protein Length	Full Length
Mol. Weight	46.2 kDa
Research Area	Others
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination in presence of Ubl-conjugating enzyme UBE2H leading to p53/TP53 degradation. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzymes (E2) at the E3:substrate complex.
Subcellular Location	Cytoplasm. Nucleus. Note=Nuclear in germ cells. Cytoplasmic in well-differentiated hepatocellular carcinoma, nuclear in moderately- and poorly-differentiated hepatocellular carcinoma.
Database References	HGNC: 13574 OMIM: 300468 KEGG: hsa:51438 STRING: 9606.ENSP00000354660 UniGene: PMID: 29257297 our findings revealed a previously unrecognized regulation of STAT3 activation in tumor cells by cancer/testis antigen MAGEC2, and provided a molecular mechanism for the oncogenic activity of MAGEC2 in cancer cells. PMID: 27775077 High MAGE-C2 expression was found in 38.18% of triple negative breast cancer tissues and in 9.09% of adjacent tissues. High MAGE-C2 expression in TNBC patients was closely associated with tumor node metastasis and shorter survival time. PMID: 27843173 our study provides a suitable cell model for exploring the biological functions of MAGEC2 in malignant cells, and sheds light on the molecular pathway by which MAGEC2 promotes tumor development. PMID: 27636589 The expressions of MAGE-C2 mRNA and MAGE-C2 protein were closely associated with stage, metastasis of lung cancer. PMID: 26903162 In gastrointestinal stromal tumors, 5/51 (10%) patients expressed MAGE-C2. High-grade GIST are more likely to express MAGE-C2. MAGE-C2 also significantly correlates with mitotic rate and tumor size. PMID: 24713551 Our results indicate that MAGEC2 has a role in breast cancer metastasis through inducing epithelial-mesenchymal transition PMID: 24687377 overexpression of HCA587 resulted in a significant enhancement of LMP1-induced IL-6 production. These data indicate that HCA587 is a new negative regulator of BS69 PMID: 24866244 MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repair. PMID: 23096706 Cytotoxic T cell clones directed against MAGE-C2 peptides recognize EB81-melanoma tumor cells treated with interferon (IotaFN)-gamma. PMID: 22925930 MAGE-C2/CT10 expression in prostate cancer correlates with the degree of malignancy and indicates a higher risk for biochemical recurrence after radical prostatectomy. PMID: 21754986 MAGEC2 is a sensitive and novel marker for seminoma. PMID: 21780320 p43-57 is the first HCA587-derived major histocompatibility complex class II-restricted epitope to fulfil all prerequisites for use as a peptide vaccine in patients with HCA587-expressing tumors PMID: 21595801 HCA 587 may be a valuable target antigen for diagnosis and vaccination of hepatocelular carcinoma patients. PMID: 12920247 identified 2 antigens encoded by gene MAGE-C2 which are recognized by several melanoma-specific cytolytic T lymphocyte clones isolated from a melanoma patient; both antigens are presented by HLA-A2 PMID: 14999777 CT10 expression was more frequently found in squamous cell carcinoma than in adenocarcinoma. PMID: 15061963 because of the expression pattern of gene MAGE-C2, this new antigen is strictly tumor-specific PMID: 17096150 the MAGE-A3 and MAGE-C2 gene promoter regions are de-methylated in the presence of activated KIT but become methylated on inhibition of KIT, consistent with the downregulation of mRNA and protein PMID: 17495964 MAGE-C2/CT-10 is expressed in hepatocellular carcinoma PMID: 18942708

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.